Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia.
Annika EwertMirko RehbergKarl Peter SchlingmannOlaf HiortUlrike John-KroegelOliver MetzingElke WühlFranz SchaeferMarkus J KemperUte DerichsAnnette Richter-UnruhLudwig PatzerNorbert AlbersDesiree DunstheimerHolger HaberlandSabine HegerCarmen SchröderNorbert JorchElmar SchmidHagen StaudeMarcus WeitzClemens FreibergMaren Leifheit-NestlerMiroslav ZivicnjakDirk SchnabelDieter Haffnernull nullPublished in: The Journal of clinical endocrinology and metabolism (2023)
In this real-world setting, 12 months of burosumab treatment was equally effective in normalizing serum ALP in adolescents and children, despite persistent mild hypophosphatemia in half of patients, suggesting that complete normalization of serum phosphate is not mandatory for substantial improvement of rickets in these patients. Adolescents appear to require lower weight-based burosumab dosage than children.